公开(公告)号：EP4100408A1

公开(公告)日：2022-12-14

申请号：EP21708812.9

申请日：2021-02-02

Applicant: Bristol-Myers Squibb Company

Inventor： AHMAD, Saleem ,  NEGASH, Lidet A.

IPC: C07D471/14 ,  C07D471/04 ,  A61P19/02 ,  A61K31/437 ,  A61P19/06 ,  A61P29/00 ,  A61P35/00

公开(公告)号：EP3209652B1

公开(公告)日：2020-04-15

申请号：EP15791146.2

申请日：2015-10-23

Applicant: Bristol-Myers Squibb Company

Inventor： WATTERSON, Scott Hunter ,  TEBBEN, Andrew J. ,  AHMAD, Saleem

IPC: C07D401/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  A61K31/435 ,  A61K31/437 ,  A61K31/538 ,  A61K31/5415 ,  A61K31/553 ,  A61P29/00 ,  A61P37/00

公开(公告)号：EP3621960A1

公开(公告)日：2020-03-18

申请号：EP18727589.6

申请日：2018-05-10

Applicant: Bristol-Myers Squibb Company

Inventor： AHMAD, Saleem ,  LI, Ling ,  NEGASH, Lidet A. ,  HYNES, John

IPC: C07D409/12 ,  C07D495/04 ,  A61P35/00 ,  A61K31/4365

公开(公告)号：EP3053912B1

公开(公告)日：2018-09-12

申请号：EP16154555.3

申请日：2012-11-30

Applicant: Bristol-Myers Squibb Company

Inventor： TURDI, Huji ,  HANGELAND, Jon J. ,  LAWRENCE, R. Michael ,  CHENG, Dong ,  AHMAD, Saleem ,  MENG, Wel ,  BRIGANCE, Robert Paul ,  DEVASTHALE, Pratik

IPC: C07D211/86 ,  C07D211/90 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/14 ,  C07F9/40 ,  A61K31/4418 ,  A61K31/4427 ,  A61P3/00

CPC classification number: A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D211/86 ,  C07D211/90 ,  C07D221/20 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07F9/4006 ,  C07F9/5352 ,  C07F9/59

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：EP1773833A2

公开(公告)日：2007-04-18

申请号：EP05775198.4

申请日：2005-07-14

Applicant: Bristol-Myers Squibb Company

Inventor： FEVIG, John, M. ,  FENG, Jianxin ,  AHMAD, Saleem

IPC: C07D471/04 ,  C07D487/02 ,  A61K31/437

CPC classification number: C07D471/04

Abstract: The present application provides pyrrolo (oxo) isoquinolines as modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

公开(公告)号：EP4004000A1

公开(公告)日：2022-06-01

申请号：EP20753623.6

申请日：2020-07-22

Applicant: Bristol-Myers Squibb Company

Inventor： AHMAD, Saleem ,  LI, Ling ,  WU, Hong ,  HYNES, John

IPC: C07D495/04 ,  C07D513/04 ,  A61K31/4365 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00

公开(公告)号：EP2785693B1

公开(公告)日：2016-05-18

申请号：EP12821212.3

申请日：2012-11-30

Applicant: Bristol-Myers Squibb Company

Inventor： TURDI, Huji ,  HANGELAND, Jon J. ,  LAWRENCE, R. Michael ,  CHENG, Dong ,  AHMAD, Saleem ,  MENG, Wei ,  BRIGANCE, Robert Paul ,  DEVASTHALE, Pratik ,  ZHAO, Guohua

IPC: C07D211/86 ,  C07D211/90 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/14 ,  C07F9/40 ,  A61K31/4418 ,  A61K31/4427 ,  A61P3/00

CPC classification number: A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D211/86 ,  C07D211/90 ,  C07D221/20 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07F9/4006 ,  C07F9/5352 ,  C07F9/598

公开(公告)号：EP2892897A1

公开(公告)日：2015-07-15

申请号：EP13765834.0

申请日：2013-09-03

Applicant: Bristol-Myers Squibb Company

Inventor： WASHBURN, William N. ,  MURUGAIAH SUBBAIAH, Murugaiah Andappan ,  AHMAD, Saleem

IPC: C07D403/12 ,  C07D401/14 ,  C07D401/12 ,  C07D403/14 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D491/10 ,  C07D295/096 ,  C07D295/135 ,  A61K31/4025 ,  A61K31/402 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/454

CPC classification number: C07D207/273 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/435 ,  A61K31/445 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  C07D295/096 ,  C07D295/135 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D491/10 ,  C07D491/107

Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments.

Abstract translation: 本发明提供了如在说明书中定义的式（I）的化合物和包含任何这种新化合物的组合物。 这些化合物是可用作药物的黑色素浓集激素受体-1（MCHR1）拮抗剂。

公开(公告)号：EP2785693A1

公开(公告)日：2014-10-08

申请号：EP12821212.3

申请日：2012-11-30

Applicant: Bristol-Myers Squibb Company

Inventor： TURDI, Huji ,  HANGELAND, Jon J. ,  LAWRENCE, R. Michael ,  CHENG, Dong ,  AHMAD, Saleem ,  MENG, Wei ,  BRIGANCE, Robert Paul ,  DEVASTHALE, Pratik ,  ZHAO, Guohua

IPC: C07D211/86 ,  C07D211/90 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/14 ,  C07F9/40 ,  A61K31/4418 ,  A61K31/4427 ,  A61P3/00

CPC classification number: A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D211/86 ,  C07D211/90 ,  C07D221/20 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07F9/4006 ,  C07F9/5352 ,  C07F9/598

Abstract: The present invention provides compounds of Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：EP2173725A2

公开(公告)日：2010-04-14

申请号：EP08772437.3

申请日：2008-07-07

Applicant: Bristol-Myers Squibb Company

Inventor： STEIN, Philip, D. ,  BISAHA, Sharon, N. ,  AHMAD, Saleem ,  NGU, Khehyong ,  WASHBURN, William, N.

IPC: C07D241/18 ,  C07D401/12

CPC classification number: C07D241/18 ,  C07D401/12

Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I, wherein, R1, R2, R3, R8, and R9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.